about
Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary studyDouble Roles of Macrophages in Human Neuroimmune Diseases and Their Animal ModelsTh17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic ImplicationsHypersensitivity Responses in the Central Nervous SystemAntibodies as Mediators of Brain PathologyNeuromyelitis optica pathology in rats following intraperitoneal injection of NMO-IgG and intracerebral needle injury.Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in miceCerebrospinal fluid aquaporin-4-immunoglobulin G disrupts blood brain barrier.Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody.Pain in neuromyelitis optica--prevalence, pathogenesis and therapy.The role of complement in neurological and neuropsychiatric diseases.Peripheral Inflammation and Demyelinating Diseases.The Role of Brain-Reactive Autoantibodies in Brain Pathology and Cognitive Impairment.Enhancing Brain Lesions during Acute Optic Neuritis and/or Longitudinally Extensive Transverse Myelitis May Portend a Higher Relapse Rate in Neuromyelitis Optica Spectrum Disorders.CD8-Positive T-Cell Leukoencephalitis With Astrocytopathy Clinically Presenting as Neuromyelitis Optica.Astrocytic Interleukin-15 Reduces Pathology of Neuromyelitis Optica in Mice.Selective localization of IgG from cerebrospinal fluid to brain parenchyma.NMO-IgG and AQP4 Peptide Can Induce Aggravation of EAMG and Immune-Mediated Muscle Weakness.
P2860
Q21558554-1E727D5C-B659-4DB2-A612-5120086A2C79Q26749131-E8E6B6A0-9B0F-4794-9920-3A0A962B286BQ26768649-3DE53397-C403-4F55-852F-F20EEDF27DE5Q26779177-9CBF9280-8922-463A-BA7B-8B5A1ED735A6Q26780374-DDA19AEF-6613-4049-9391-828154782523Q34529121-1B5EEB3C-C120-477E-8FCA-B38DD57E3A10Q34842262-EDF51A29-915D-4752-8315-712776156D5DQ36010441-81B784AA-7979-4F04-9572-B65FA7433E21Q36348690-ED911E10-6A29-4610-A1CB-34B87C0D8CCDQ38235026-B9BC269D-2B52-4457-851B-5B5DC540201CQ38590250-D64376FF-9A0B-4C38-A7B1-F011545B15FDQ38974745-56B7F823-493B-474B-8D80-4F82FDB41A8EQ41684146-6E7C9183-57F6-4157-B14A-BF150B43C006Q43067194-FFA7C89E-E9F7-436F-88E9-E4212538DBC7Q47816982-D163018A-C71B-4CEC-8D75-8DDC844ED2D0Q53698580-16428222-FDF4-42B3-9416-37209471708EQ55332083-3EFFD992-6690-4F65-A6DE-7E63BE22442BQ55384506-DBE4E113-3414-4A1D-91FF-96266004DD71
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Experimental models of neuromyelitis optica.
@ast
Experimental models of neuromyelitis optica.
@en
type
label
Experimental models of neuromyelitis optica.
@ast
Experimental models of neuromyelitis optica.
@en
prefLabel
Experimental models of neuromyelitis optica.
@ast
Experimental models of neuromyelitis optica.
@en
P2860
P356
P1433
P1476
Experimental models of neuromyelitis optica
@en
P2093
Hans Lassmann
Monika Bradl
P2860
P356
10.1111/BPA.12098
P5008
P577
2014-01-01T00:00:00Z